title: [PET-CT in the oncological translational platforms].
abstract: Molecular Imaging is changing the development of new therapies. Conventional imaging methods evaluate response based in the reduction of tumour size, which often is a late effect and, therefore, it can take months to confirm the efficacy of an antitumoral therapy. Systems based in imaging biomarkers or radiotracers, as PET and PET-CT can detect the response as soon as a few days after initiation of therapy. A large number of imaging radiotracers has been proposed. They are capable of supplying a varied information: metabolism, cellular proliferation, DNA replication, protein or membrane lipids synthesis, amino acid transport, angiogenesis, hypoxia, apoptosis, etc.
authors.forename: José Luis
authors.initials: JL
authors.lastname: Carreras Delgado
mesh_terms: D006801:Humans; D064847:Multimodal Imaging; D009369:Neoplasms / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography; D014057:Tomography, X-Ray Computed